Savvy Trades and Investments

[RNsidersbuying]

VXRT .71 - continue to own a boatload...you just don't see under-a-buck biotechs receive such a huge commitment from the government? Looking forward to the first dosing...

Funds from the BARDA award will be used to conduct a 10,000-subject Phase 2b comparative study evaluating Vaxart’s oral pill COVID-19 vaccine candidate against a U.S. Food and Drug Administration (FDA)-approved mRNA vaccine comparator. With manufacturing preparations substantially complete and funding in place, Vaxart plans to initiate enrollment in this trial as early as summer 2024, pending regulatory alignment. An interim analysis for vaccine efficacy compared to an approved mRNA comparator may occur as early as the first quarter of 2025.

https://capedge.com/filing/72444/0001437749-24-020543/VXRT-8K/file/2